Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
Michael Dougan, Ajay Nirula, Masoud Azizad, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 15, pp. 1382-1392
Open Access | Times Cited: 405

Showing 26-50 of 405 citing articles:

Hybridoma technology; advancements, clinical significance, and future aspects
Sanchita Mitra, Pushpa C. Tomar
Journal of Genetic Engineering and Biotechnology (2021) Vol. 19, Iss. 1, pp. 159-159
Open Access | Times Cited: 102
Deep learning guided optimization of human antibody against SARS-CoV-2 variants with broad neutralization
Sisi Shan, Shitong Luo, Ziqing Yang, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 11
Open Access | Times Cited: 100
Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial
Thomas L Holland, Adit A. Ginde, Roger Paredes, et al.
The Lancet Respiratory Medicine (2022) Vol. 10, Iss. 10, pp. 972-984
Open Access | Times Cited: 99
Multivalent designed proteins neutralize SARS-CoV-2 variants of concern and confer protection against infection in mice
Andrew C. Hunt, James Brett Case, Young‐Jun Park, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 646
Open Access | Times Cited: 97
Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities
Steven Lim, Chee Peng Hor, Kim Heng Tay, et al.
JAMA Internal Medicine (2022) Vol. 182, Iss. 4, pp. 426-426
Open Access | Times Cited: 89
COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes
Daniele Focosi, Massimo Franchini, Liise-anne Pirofski, et al.
Clinical Microbiology Reviews (2022) Vol. 35, Iss. 3
Open Access | Times Cited: 89
SARS-CoV-2 BA.1 variant is neutralized by vaccine booster–elicited serum but evades most convalescent serum and therapeutic antibodies
Sabrina Lusvarghi, Simon Pollett, Sabari Nath Neerukonda, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 645
Open Access | Times Cited: 87
Development of therapeutic antibodies for the treatment of diseases
Zeng Wang, Guoqing Wang, Huaqing Lu, et al.
Molecular Biomedicine (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 75
Therapeutics for COVID-19 and post COVID-19 complications: An update
Debdoot Basu, Vivek P. Chavda, Anita A. Mehta
Current Research in Pharmacology and Drug Discovery (2022) Vol. 3, pp. 100086-100086
Open Access | Times Cited: 68
Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agents
Norberto Perico, Monica Cortinovis, Fredy Suter, et al.
The Lancet Infectious Diseases (2022) Vol. 23, Iss. 1, pp. e22-e33
Open Access | Times Cited: 66
Antiviral neutralizing antibodies: from in vitro to in vivo activity
Dennis R. Burton
Nature reviews. Immunology (2023) Vol. 23, Iss. 11, pp. 720-734
Open Access | Times Cited: 62
A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir
Jacqueline G. Gerhart, Donna S. Cox, Ravi Shankar Prasad Singh, et al.
Clinical Pharmacokinetics (2024) Vol. 63, Iss. 1, pp. 27-42
Open Access | Times Cited: 20
Mucosal immune response in biology, disease prevention and treatment
Xiaoxue Zhou, Yuchen Wu, Zhipeng Zhu, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 2
Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis
Reed Siemieniuk, Jessica Bartoszko, Juan Pablo Díaz Martinez, et al.
BMJ (2021), pp. n2231-n2231
Open Access | Times Cited: 75
A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load
Michael Dougan, Masoud Azizad, Bharat Mocherla, et al.
Clinical Infectious Diseases (2021) Vol. 75, Iss. 1, pp. e440-e449
Open Access | Times Cited: 63
Pharmacological treatment of COVID-19: an opinion paper
Alberto García‐Lledó, Javier Gómez‐Pavón, Juan González del Castillo, et al.
Revista Española de Quimioterapia (2021) Vol. 35, Iss. 2, pp. 115-130
Open Access | Times Cited: 62
Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper
Thomas Marjot, Christiane S. Eberhardt, Tobias Boettler, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 4, pp. 1161-1197
Open Access | Times Cited: 62
Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses
Judith M. White, Joshua T. Schiffer, Rachel Bender Ignacio, et al.
mBio (2021) Vol. 12, Iss. 6
Open Access | Times Cited: 57
The impact of neutralizing monoclonal antibodies on the outcomes of COVID‐19 outpatients: A systematic review and meta‐analysis of randomized controlled trials
Wei‐Ting Lin, Shun‐Hsing Hung, Chih‐Cheng Lai, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 5, pp. 2222-2229
Open Access | Times Cited: 56
Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19
Matthew G. Johnson, Amy Puenpatom, Pablo Andrés Moncada, et al.
Annals of Internal Medicine (2022) Vol. 175, Iss. 8, pp. 1126-1134
Open Access | Times Cited: 55
Recent review of COVID-19 management: diagnosis, treatment and vaccination
Vivek P. Chavda, Suneetha Vuppu, Toshika Mishra, et al.
Pharmacological Reports (2022) Vol. 74, Iss. 6, pp. 1120-1148
Open Access | Times Cited: 55
Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies
Timothée Bruel, Karl Stéfic, Yann Nguyen, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 12, pp. 100850-100850
Open Access | Times Cited: 54
Real-World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients
Neil R. Aggarwal, Laurel Beaty, Tellen D. Bennett, et al.
The Journal of Infectious Diseases (2022) Vol. 226, Iss. 12, pp. 2129-2136
Open Access | Times Cited: 48
High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial
Dora Buonfrate, Fabio Chesini, Davide Martini, et al.
International Journal of Antimicrobial Agents (2022) Vol. 59, Iss. 2, pp. 106516-106516
Open Access | Times Cited: 47
Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19
Kara W. Chew, Carlee Moser, Eric S. Daar, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 43

Scroll to top